As of April 28, 2026, Replimune's top three insider holders are Fund Iv, L.P. Omega (TenPercentOwner, 9.44Mn shares), Fund Iv, L.P. Omega (TenPercentOwner, 9.44Mn shares), Robert Coffin (President Chief Rd Officer, 1.82Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Fund Iv, L.P. Omega | - | 4,673,380 | 4,763,380 | 16 Mar, 2022 |
| Fund Iv, L.P. Omega | - | 4,673,380 | 4,763,380 | 16 Mar, 2022 |
| Robert Coffin | President Chief Rd Officer | 1,821,872 | 0 | 20 May, 2024 |
| Philip Astley-Sparke | Executive Chairman | 1,430,071 | 0 | 07 Apr, 2026 |
| Colin Love | Chief Operating Officer | 777,345 | 0 | 20 May, 2024 |
| Sushil Patel | Chief Executive Officer | 533,576 | 0 | 19 Dec, 2025 |
| Pamela Esposito | Chief Business Officer | 263,436 | 0 | 13 Sep, 2023 |
| Konstantinos Xynos | Chief Medical Officer | 249,685 | 0 | 07 Apr, 2026 |
| Konstantinos Xynos | Chief Medical Officer | 199,685 | 0 | 19 Dec, 2025 |
| Emily Luisa Hill | Chief Financial Officer | 194,368 | 0 | 19 Dec, 2025 |
| Christopher Sarchi | Chief Commercial Officer | 151,588 | 0 | 06 Apr, 2026 |
| Tanya Lewis | Chief Dev. Op. Officer | 135,293 | 0 | 15 Jun, 2023 |
| Jean M. Franchi | Chief Financial Officer | 128,748 | 0 | 18 May, 2023 |
| Andrew Schwendenman | Chief Accounting Officer | 114,951 | 0 | 07 Apr, 2026 |
| Andrew Schwendenman | Chief Accounting Officer | 78,284 | 0 | 19 Dec, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 01 Apr, 2026 | Andrew Schwendenman | Common Stock | D | 36,667 | $0.00 | 114,951 | D | A |
| 01 Apr, 2026 | Dieter Weinand | Stock Option (right to buy) | A | 44,500 | $0.00 | 44,500 | D | A |
| 01 Apr, 2026 | Madhavan Balachandran | Stock Option (right to buy) | A | 44,500 | $0.00 | 44,500 | D | A |
| 01 Apr, 2026 | Konstantinos Xynos | Common Stock | A | 50,000 | $0.00 | 249,685 | D | A |
| 01 Apr, 2026 | Kapil Dhingra | Stock Option (right to buy) | A | 44,500 | $0.00 | 44,500 | D | A |
| 01 Apr, 2026 | Veleka Peeples-Dyer | Stock Option (right to buy) | A | 44,500 | $0.00 | 44,500 | D | A |
| 01 Apr, 2026 | Emily Luisa Hill | Common Stock | A | 50,000 | $0.00 | 244,368 | D | A |
| 01 Apr, 2026 | Christopher Sarchi | Common Stock | A | 50,000 | $0.00 | 201,588 | D | A |
| 01 Apr, 2026 | Christy J. Oliger | Stock Option (right to buy) | A | 44,500 | $0.00 | 44,500 | D | A |
| 01 Apr, 2026 | Joseph P Slattery | Stock Option (right to buy) | A | 44,500 | $0.00 | 44,500 | D | A |
| 01 Apr, 2026 | Paolo Pucci | Stock Option (right to buy) | A | 44,500 | $0.00 | 44,500 | D | A |
| 01 Apr, 2026 | Philip Astley-Sparke | Common Stock | A | 50,000 | $0.00 | 1,430,071 | D | A |
| 01 Apr, 2026 | Andrew Schwendenman | Employee Stock Option (right to buy) | A | 55,000 | $0.00 | 55,000 | D | A |
| 01 Apr, 2026 | Christopher Sarchi | Employee Stock Option (right to buy) | A | 75,000 | $0.00 | 75,000 | D | A |
| 01 Apr, 2026 | Konstantinos Xynos | Employee Stock Option (right to buy) | A | 75,000 | $0.00 | 75,000 | D | A |
| 01 Apr, 2026 | Philip Astley-Sparke | Stock Option (right to buy) | A | 75,000 | $0.00 | 75,000 | D | A |
| 01 Apr, 2026 | Emily Luisa Hill | Employee Stock Option (right to buy) | A | 75,000 | $0.00 | 75,000 | D | A |
| 02 Apr, 2026 | Christopher Sarchi | Common Stock | D | 6,500 | $8.01 | 151,588 | D | S |
| 18 Feb, 2026 | Philip Astley-Sparke | Common Stock | D | 25,000 | $0.00 | 1,380,071 | D | G |
| 19 Dec, 2025 | Andrew Schwendenman | Common Stock | A | 10,000 | $0.00 | 78,284 | D | A |